Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

Alba A. Brandes, E. Franceschi, Thierry Gorlia, Wolfgang Wick, A. H. Jacobs, B. G. Baumert, Martin J. van den Bent, C.M. Weller, Roger Stupp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)896-903
JournalEuropean Journal of Cancer
Issue number6
Publication statusPublished - Apr 2012


  • Recurrent glioblastoma
  • End-points
  • Overall survival
  • Progression-free survival
  • Overall survival rates

Cite this